A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected markers of tumour burden and immunological status, and disease outcome.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer|
- No clinically relevant deleterious effect of IMM-101 on safety and tolerability. [ Time Frame: After 12 months or as clinically indicated ] [ Designated as safety issue: Yes ]
A clinically relevant deleterious effect of IMM-101 on safety and tolerability profiles will be judged by:
- Local and systemic toxicities.
- Number, type and degree of toxicities as measured by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v4.0.
- QoL (EORTC QLQ-C30 questionnaire supplemented by the pancreas cancer specific EORTC QLQ-PAN26 questionnaire).Efficacy will be defined as a clinically relevant improvement in one or more markers of disease status.
- A clinically relevant improvement in one or more markers of disease status [ Time Frame: 12 months or as clinically indicated ] [ Designated as safety issue: No ]
A clinically relevant improvement in one or more markers of disease status:
- Overall survival (OS).
- Progression-free survival (PFS).
- Overall response rate (ORR).
- Reduction in metastatic disease.
- Circulating levels of carbohydrate antigen 19.9 (CA19.9).
- Circulating levels of carcinoembryonic antigen (CEA).
- Nutritional status (weight, appetite, serum albumin).
- Pain control and analgesic use.
- Immunological markers [ Time Frame: 12 months or as clinically indicated ] [ Designated as safety issue: No ]
Blood samples will be collected from all patients for analysis of immunological markers and mediators (e.g. cytokines and antibodies, any other immunologically relevant assays.
For a subset of patients cells will be isolated from the whole blood samples. Exploratory endpoints may include:
- A change in levels of circulating tumour cells (CTCs)
- A change in one or more markers of immune status
|Study Start Date:||June 2011|
|Estimated Study Completion Date:||April 2014|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Active Comparator: gemcitabine chemotherapy
Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal orescribing information for pancreatic cancer.
Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.
Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).
Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol.
Other Name: Gemzar
Experimental: IMM-101 in addition to gemcitabine
Patients in the experiemental arm will recieve IMM-101 in addition the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.
For patients in the active group, chemotherapy (GEM) will begin at least 14 days after first dose of IMM-101.
Chemotherapy plus IMM-101 will be offered until intolerable toxcity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).
IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL)will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.
Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine.
Other Name: Heat killed whole cell Mycobacterium obuense, M. obuense
|Contact: Angus Dalgleish, Professor||+44 (0) 20 8725 email@example.com|
|Contact: Hilary Bilyard, Dr.||+44 (0)203 219 firstname.lastname@example.org|
|Cyprus Oncology Centre||Recruiting|
|Nicosia, Strovolos, Cyprus, 2006|
|Contact: Demitris Papamichael 0035 7228413006 email@example.com|
|Principal Investigator: Demitris Papamichael|
|Adelaide, Meath & National Childrens Hospital,||Recruiting|
|Dublin, Ireland, Dublin 24|
|Contact: Ray McDermott|
|Principal Investigator: Ray McDermott|
|St Vicents University Hospital||Recruiting|
|Dublin, Ireland, Dublin 4|
|Contact: Ray McDermott|
|Principal Investigator: Ray McDermott|
|A.O. Santa Croce e Carle, Struttura Complessa di Oncologia Medica||Recruiting|
|Confreria, Cuneo, Italy|
|Contact: Granetto, Dr : +39 0171 616738 firstname.lastname@example.org|
|Principal Investigator: Granetto, Dr|
|Azienda Ospedaliero-Universitaria di Bologna||Completed|
|Bologna, Italy, 40138|
|Brescia, Italy, 25124|
|Azienda Ospedaliera San Gerardo Struttura Complessa Oncologia Medica||Recruiting|
|Monza, Italy, 20052|
|Contact: Bidoli +39 039 23395754 email@example.com|
|Principal Investigator: Paolo Bidoli|
|AOU Maggiore della Carità||Recruiting|
|Contact: OSCAR ALABISO +3903213733068 firstname.lastname@example.org|
|Principal Investigator: OSCAR ALABISO|
|Medical Oncology Department, Central University Hospital of Asturias||Recruiting|
|Asturias, Oviedo, Spain|
|Contact: José María Vieitez de Prado +34 985 108 000|
|Principal Investigator: Jose Maria Vietitez De Prado, Dr.|
|Hospital General de Alicante||Recruiting|
|Alicante, Spain, 03010|
|Contact: Bartomeu Massutti, Dr. + 34699439910 email@example.com|
|Contact + 34965259654|
|Principal Investigator: Bartomeu Massutti, Dr.|
|Hospital Gregorio Marañon||Recruiting|
|Madrid, Spain, 28007|
|Contact: Andres Muñoz, Dr +34 91 426 90 70 firstname.lastname@example.org|
|Principal Investigator: Andres Munoz, Dr|
|Instituto Valenciano de Oncologia||Recruiting|
|Valencia, Spain, 46009|
|Contact: Carlos Fernandez - Martos +34 961114013 email@example.com|
|Principal Investigator: Carlos Fernandez-Martos|
|Department of Medical Oncology, Hospital Universitari La Fe,||Recruiting|
|Contact: Roberto Pedro Diaz Beveridge, Dr. :+34 961 24 40 00|
|Principal Investigator: Roberto Pedro Diaz Beveridge, Dr.|
|Hospital Miguel Servet||Recruiting|
|Zaragoza, Spain, 50009|
|Contact: Roberto Pazo +34 976 359 268 ext 3825 firstname.lastname@example.org|
|Principal Investigator: Roberto Pazo|
|Airedale General Hospital||Recruiting|
|Skipton, West Yorkshire, United Kingdom, BD20 6TD|
|Contact 01535 292839 email@example.com|
|Principal Investigator: Sue Cheeseman, Dr.|
|Royal Blackburn Hospital||Recruiting|
|Blackburn, United Kingdom, BB2 3HH|
|Contact: Ajay Mehta, Dr + 44(0)1254 734 019 Ajay.Mehta@lthtr.nhs.uk|
|Principal Investigator: Ajay Mehta, Dr|
|Bradford Royal Infirmary||Recruiting|
|Bradford, United Kingdom, BD9 6RJ|
|Contact: Sue Cheeseman 01274 382455 firstname.lastname@example.org|
|Principal Investigator: Sue Cheeseman|
|Velindre Cancer Centre||Recruiting|
|Cardiff, United Kingdom, Velindre Cancer Centre|
|Contact: Seema Arif 029 2019 6184 SEEMA.ARIF@WALES.NHS.UK|
|Principal Investigator: Seema Arif|
|Dundee, United Kingdom, DD1 9SY|
|Contact: Douglas Adamson, Dr 01382 660111|
|Principal Investigator: Douglas Adamson|
|The London Clinic Cancer Centre||Completed|
|London, United Kingdom, W1G 6BW|
|Mount Vernon Cancer Centre||Recruiting|
|London, United Kingdom, HA6 2RN|
|Contact: Rob Glynne-Jones 01923 844767 email@example.com|
|Principal Investigator: Rob Glynne-Jones|
|Peterbrough City Hospital, Haematology/Oncology Dept,||Recruiting|
|Peterborough, United Kingdom, PE3 9GZ|
|Contact: Karen McAdam, Dr 01733 673188 firstname.lastname@example.org|
|Principal Investigator: Karen McAdam, Dr.|
|Principal Investigator:||Angus Dalgleish, Professor||St George's, University of London|